Plain-English translation of NCT07104487 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Researchers are testing a new imaging technology called [18F]AlF-NOTA-octreotide PET/MRI to better understand the plaques building up in carotid arteries (the major blood vessels in your neck that supply blood to your brain). This imaging scan combines two types of imaging into one, and the medication helps doctors see which plaques are most likely to cause problems. The study wants to see if this scan can predict which patients are at higher risk of having another stroke.
Currently, doctors have limited tools to predict which patients with carotid artery disease will have another stroke. This new imaging scan may help identify the most dangerous plaques and better inform treatment decisions to prevent future strokes.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will have a screening visit, then undergo the specialized PET/MRI imaging scan. After that, you will have three follow-up phone calls at 90 days, 1 year, and 3 years to check on your health and see if you have had any stroke-related events. The first 5 participants will have imaging scans at three different time points to help the researchers optimize the timing, while the remaining 19 participants will have one scan at the optimal time determined from the first group.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
Belgium